Preservation of residual kidney function in hemodialysis patients: reviving an old concept

Anna T Mathew, Steven Fishbane, Yoshitsugu Obi, Kamyar Kalantar-Zadeh, Anna T Mathew, Steven Fishbane, Yoshitsugu Obi, Kamyar Kalantar-Zadeh

Abstract

Residual kidney function (RKF) may confer a variety of benefits to patients on maintenance dialysis. RKF provides continuous clearance of middle molecules and protein-bound solutes. Whereas the definition of RKF varies across studies, interdialytic urine volume may emerge as a pragmatic alternative to more cumbersome calculations. RKF preservation is associated with better patient outcomes including survival and quality of life and is a clinical parameter and research focus in peritoneal dialysis. We propose the following practical considerations to preserve RKF, especially in newly transitioned (incident) hemodialysis patients: (1) periodic monitoring of RKF in hemodialysis patients through urine volume and including residual urea clearance with dialysis adequacy and outcome markers such as anemia, fluid gains, minerals and electrolytes, nutritional, status and quality of life; (2) avoidance of nephrotoxic agents such as radiocontrast dye, nonsteroidal anti-inflammatory drugs, and aminoglycosides; (3) more rigorous hypertension control and minimizing intradialytic hypotensive episodes; (4) individualizing the initial dialysis prescription with consideration of an incremental/infrequent approach to hemodialysis initiation (e.g., twice weekly) or peritoneal dialysis; and (5) considering a lower protein diet, especially on nondialysis days. Because RKF appears to be associated with better patient outcomes, it requires more clinical and research focus in the care of hemodialysis and peritoneal dialysis patients.

Keywords: end-stage renal disease; incremental hemodialysis; residual kidney function.

Conflict of interest statement

Relevant Potential Conflict of Interest:

KKZ has received honoraria and/or support from Abbott, Abbvie, Alexion, Amgen, ASN, Astra-Zeneca, Aveo, Chugai, DaVita, Fresenius, Genetech, Haymarket Media, Hospira, Kabi, Keryx, NIH, NKF, Relypsa, Resverlogix, Sanofi, Shire, Vifor, ZS-Pharma.

Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Schematic of the Preservation of the RKF in Hemodialysis Patients.

Source: PubMed

3
Iratkozz fel